Online inquiry

IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1241MR)

This product GTTS-WQ1241MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets DLL4&VEGFA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_019074.4; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 54567; 7422
UniProt ID Q9NR61; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1241MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5578MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ2186MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ11217MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ10206MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ1290MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ14074MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3918
GTTS-WQ7226MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ11825MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MK-4280
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW